These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31162631)

  • 1. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 2. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 3. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.
    Kearns GL; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61(6):740-743. PubMed ID: 33797778
    [No Abstract]   [Full Text] [Related]  

  • 4. Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.
    Rose K; Tanjinatus O; Grant-Kels JM; Ettienne EB; Striano P; Neubauer D
    J Clin Pharmacol; 2021 Jun; 61(6):736-739. PubMed ID: 33368372
    [No Abstract]   [Full Text] [Related]  

  • 5. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings of a Workshop: US Food and Drug Administration-International Society of Pharmacometrics Model-Informed Drug Development in Oncology.
    Bruno R; Jin JY; Maxfield K; Milligan L; Liu C; Wang Y; McKee AE; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):81-83. PubMed ID: 30951201
    [No Abstract]   [Full Text] [Related]  

  • 7. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration.
    Reaman G; Karres D; Ligas F; Lesa G; Casey D; Ehrlich L; Norga K; Pazdur R
    J Clin Oncol; 2020 Dec; 38(36):4227-4230. PubMed ID: 32946356
    [No Abstract]   [Full Text] [Related]  

  • 9. Discussion: The role, position, and function of the FDA-The past, present, and future.
    Fleming TR; Demets DL; McShane LM
    Biostatistics; 2017 Jul; 18(3):417-421. PubMed ID: 28633307
    [No Abstract]   [Full Text] [Related]  

  • 10. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 11. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 12. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 14. Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.
    Ménard T; Young K; Siegel L; Emerson J; Studt R; Sidor L;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):799-803. PubMed ID: 34247450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA's patient-focused drug development initiative.
    Kluetz PG; Bhatnagar V
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):70-72. PubMed ID: 33596186
    [No Abstract]   [Full Text] [Related]  

  • 16. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 17. Reacting to crises: The COVID-19 impact on biostatistics/epidemiology.
    O'Neill RT
    Contemp Clin Trials; 2021 Mar; 102():106214. PubMed ID: 33186685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 19. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.